SCHEMBL8198110

SCHEMBL8198110

Cn1ncc2c(=O)[nH]c(C(=O)O)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
PTGS2 P35354 2/20 0.44
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
TNKS O95271 2/20 0.38
TNKS2 Q9H2K2 2/20 0.38
ATAD2 Q6PL18 1/20 0.37
DAPK3 O43293 2/20 0.37
PIM1 P11309 2/20 0.37
PIM3 Q86V86 2/20 0.37
DAPK1 P53355 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
DAPK2 Q9UIK4 1/20 0.36
LMNA P02545 1/20 0.36
PDE5A O76074 2/20 0.36
TP53 P04637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20240237 0.86 ALDH1A1 (0.46) ALDH1A1PTGS2CDK4CCND1TNKS
SCHEMBL20240233 0.84 PTGS2 (0.47) ALDH1A1PTGS2TNKSTNKS2LMNA
SCHEMBL4697070 0.80 PTGS2 (0.56) ALDH1A1PTGS2HPGDTSHRMEN1
SCHEMBL889723 0.77 CDK4 (0.55) ALDH1A1CDK4CCND1TNKS2LMNA
SCHEMBL13343675 0.77 PTGS2 (0.67) ALDH1A1PTGS2DAPK3PIM1PIM3
SCHEMBL8198106 0.76 PTGS2 (0.44) ALDH1A1PTGS2CDK4CCND1LMNA
SCHEMBL889777 0.76 ALDH1A1 (0.56) ALDH1A1CDK4CCND1PDE2AF7
SCHEMBL3424725 0.76 ALDH1A1 (0.51) ALDH1A1CDK4CCND1TNKSTNKS2
SCHEMBL8114828 0.76 ALDH1A1 (0.51) ALDH1A1CDK4CCND1TNKSTNKS2
SCHEMBL27663568 0.75 HPGD (0.39) ALDH1A1PTGS2CDK4CCND1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1871/4885PTGS2 681/4885CDK4 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.